Key milestone reached in adaptive Phase 1/1b clinical trial that began in April 2019 Cambridge, MA, October 21, 2019 – Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), today announced that the first IPF patient has been […]
Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965
